Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
H. S. Nam, W. J. Koh, S. H. Park, S. H. Kim, C. R. Ham, S. W. Um, G. Y. Suh, M. P. Chung, H. Kim, O. J. Kwon (Seoul, Republic Of Korea). Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis. Eur Respir J 2008; 32: Suppl. 52, 1357

Member's Comments

No comment yet.

Related content which might interest you: Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2013; 42: 504-512 Year: 2013 What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis? Source: Eur Respir J 2009; 34: 1492-1494 Year: 2009 Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1601724; DOI: 10.1183/13993003.01724-2016 Year: 2017 Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients Source: Eur Respir J 2013; 42: 1614-1621 Year: 2013 Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1601612; DOI: 10.1183/13993003.01612-2016 Year: 2017 Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis Source: Eur Respir J 2016; 47: 1229-1234 Year: 2016 The efficacy of a rifabutin-containing regimen for rifabutin-susceptible multidrug-resistant tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Efficacy and tolerability of linezolid in multidrug-resistant tuberculosis (MDR/XDR-TB) Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017 Year: 2017 Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis Source: Eur Respir J, 53 (1) 1801154; 10.1183/13993003.01154-2018 Year: 2019 Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? Source: Eur Respir J 2016; 48: 582-585 Year: 2016 Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Administration of linezolid, bedaquiline and imipenem in treatment of patients with extensively drug-resistant tuberculosis Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 The individual-tailored treatment regimens for multidrug-resistant tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Safety and efficacy of linezolid, clarithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 587s Year: 2006 Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India Source: Eur Respir J 2012; 39: 956-962 Year: 2012 Linezolid in multidrug-resistant tuberculosis treatment Source: Eur Respir J 2004; 24: Suppl. 48, 485s Year: 2004 Clinical efficacy and safety of clarithromycin in the treatment of multi-drug resistant tuberculosis Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009 Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005 Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy Source: Eur Respir J 2001; 17: 641-646 Year: 2001